Integrative Analysis of Large-cell Lung Cancer

Lung Cancer Clinical Trial

— LCLC  

Official title:

Integrative Analysis of Large-cell Lung Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02917369
• Other study ID #: 2016-52-Rainy
• Status: Recruiting
• Phase: N/A
• First received: September 27, 2016
• Last updated: September 27, 2016
• Start date: January 2016
• Est. completion date: December 2026

Study information

• Verified date: September 2016
• Source: Shanghai 10th People's Hospital
• Contact: Da Fu, PhD
• Phone: 00-86-21-66301604
• Email: fu800da900[@]126.com
• Is FDA regulated: No
• Health authority: China: Shanghai Municipal Commission of Health and Family Planning
• Study type: Observational

Clinical Trial Summary

Integrative analysis of LCLC

Description:

The investigators will analyzed proteomes of paired normal lung tissues and LCLC with or without liver metastasis, sequenced transcriptomes, perform whole exome sequencing, and single nucleotide polymorphism (SNP) array profiling for triplets, each comprising normal lung tissue, primary LCLC carcinoma, and its synchronous matched metastasis, as well as analyzed genomics of lung cancer characterized previously by The Cancer Genome Atlas (TCGA) to conduct integrated proteogenomic analyses.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: December 2026
• Est. primary completion date: December 2026
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age = 75 years with histologically proven LCLC

• No severe major organ dysfunction

• World Health Organization (WHO) performance status of 0 or 1

• No prior cancer chemotherapy

Exclusion Criteria:

• Age = 76

• Severe major organ dysfunction

• WHO performance status of >1

• Prior cancer chemotherapy

Study Design

Observational Model: Case Control, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

Intervention

Other:
• Normal lung tissue
The investigators will extract total protein, DNA and RNA from LCLC patients.

Locations

Country	Name	City	State
China	Ganzhou City People's Hospital	Ganzhou	Jiangxi
China	Shanghai Pulmonary Hospital	Shanghai	Shanghai
China	Shanghai Tenth People's Hospital	Shanghai	Shanghai

Sponsors (2)

Lead Sponsor	Collaborator
Shanghai 10th People's Hospital	Shanghai Pulmonary Hospital, Shanghai, China

Country where clinical trial is conducted

China, 

References & Publications (1)

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	5 years overall survival		5 years	Yes
Secondary	5 years disease-free survival		5 years	Yes